Blood thinners for preventing another clot in low-risk APS
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have antiphospholipid syndrome (APS) with a history of blood clots.
- Your APS must be low risk, meaning you had a clot in a vein before and test positive for one or two specific antibodies (not all three).
- You are already on a blood thinner like a DOAC or warfarin to prevent more clots.
- You have been taking this blood thinner steadily for at least 2 weeks before joining the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of blood thinners (DOACs like rivaroxaban or apixaban, and vitamin K blockers like warfarin) in people with antiphospholipid syndrome who had a vein clot. The goal is to see which one works better at preventing future clots without causing more bleeding.
This study observes patients with antiphospholipid syndrome who are taking or have taken direct oral anticoagulants (blood thinners) to better understand their treatment experiences and outcomes.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
This study compares two types of blood thinners (vitamin K antagonists) in people with antiphospholipid syndrome, a condition where the immune system attacks healthy cells and increases blood clot risk. The goal is to see if one is better at preventing future blood clots.
This study tests whether it is safe to stop taking blood thinners (vitamin K antagonists) if the antiphospholipid antibodies that caused your condition have been gone for at least a year. If you qualify, stopping treatment might reduce your risk of bleeding and improve your quality of life.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.